# Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.

> **NCT01204177** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 70 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** BAY86-9766 MEK Inhibitor + Sorafenib

## Key facts

- **NCT ID:** NCT01204177
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-08
- **Final completion:** 2013-08
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2013-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204177, "Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01204177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*